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Abstract
Innovative new genome engineering technologies for manipulating chromosomes have appeared in the last
decade. One of these technologies, recombination mediated genetic engineering (recombineering) allows for
precision DNA engineering of chromosomes and plasmids in Escherichia coli. Single-stranded DNA recombineering
(SSDR) allows for the generation of subtle mutations without the need for selection and without leaving behind
any foreign DNA. In this review we discuss the application of SSDR technology in lactic acid bacteria, with an
emphasis on key factors that were critical to move this technology from E. coli into Lactobacillus reuteri and
Lactococcus lactis. We also provide a blueprint for how to proceed if one is attempting to establish SSDR
technology in a lactic acid bacterium. The emergence of CRISPR-Cas technology in genome engineering and its
potential application to enhancing SSDR in lactic acid bacteria is discussed. The ability to perform precision
genome engineering in medically and industrially important lactic acid bacteria will allow for the genetic
improvement of strains without compromising safety.
Introduction
Genetics has been, and will continue to be, an essential
tool for providing insight into molecular and biological
function in all forms of life. For example, the tempera-
ture-sensitive lethal genetic screens performed in the
1960s and 70s in microbes were essential initial steps in
providing a foundation for our current understanding of
how DNA replication, transcription, and translation take
place within the cell. Many of the molecular genetic
tools in use today were originally developed in model
organisms, such as Escherichia coli and Bacillus subtilis.
Over the last 25 years many of these tools have been
successfully adapted for use in lactic acid bacteria
(LAB), including suicide plasmids for generating gene
disruptions and the development of inducible expression
systems for regulated protein production. For more
information on tools currently in use in lactic acid bac-
teria, readers are directed to the following reference as a
starting point [1]. In this review, we will highlight a
newly developed technology, single-stranded DNA
recombineering, which allows for precision genome
engineering of bacteria. Recombineering and other
emerging genome engineering tools can generate bacter-
ial strains that are genetically indistinguishable from an
organism whose genome has been altered by a natural
selection procedure. A genetically modified organism
(GMO) generated by precision genome engineering will
blur the lines between the safety profiles of organisms
traditionally considered as genetically modified organ-
isms (GMO) and those organisms that have genetically
altered genomes but are not considered GMO.
Review
Introduction to recombineering technology
In the past decade, the use of phage-encoded recombi-
nases has led to multiple applications of recombineering
(recombination-mediated genetic engineering) for in
vivo genetic engineering in Escherichia coli. Two forms
of recombineering, denoted here as double-stranded
DNA (dsDNA) and single-stranded DNA (ssDNA)
recombineering, have been described [2]. Initial studies
focused on the use of the phage-derived lambda red
locus, which consists of two genes involved in recombi-
nation (exo, beta), and subsequently two genes from the
Rac prophage (recE and recT) (for review see [3]). Beta
and RecT are ssDNA binding proteins that promote the
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annealing of complementary DNA and are often
referred to as recombinases. Exo and RecE are exonu-
cleases required to process dsDNA molecules to ssDNA
intermediates for binding by Beta or RecT, respectively.
dsDNA recombineering has been used for several differ-
ent applications, including the insertion of DNA using
as little as 50 bp of flanking homology on each end and
subcloning DNA fragments by recombineering. This
approach has been shown in E. coli to generate inser-
tions up to 2.5 kb in length [4]. As dsDNA recombi-
neering is not the subject of this review we direct
readers to the following references (and references
therein) for more information [2,5-7].
ssDNA recombineering (SSDR) allows for the engi-
neering of subtle mutations in the chromosome without
the need for any type of selection. The only require-
ments for SSDR are the inducible expression of a
recombinase (Beta or RecT) and the ability to transform
an oligonucleotide into the cell that harbors the desired
base changes to be incorporated into the chromosome.
When performed under appropriate conditions in
E. coli, up to 50% of cells that are electroporated with
the oligonucleotide will incorporate the mutation into
the chromosome, obviating the need for antibiotic selec-
tion to recover the mutation [8-10]. Recombinants are
easily identified using techniques such as MAMA-PCR,
PCR coupled with restriction digest if the mutation
alters a restriction site, or PCR amplification and
sequencing after colony purification (see below).
To achieve such high efficiencies in E. coli, several key
aspects of oligonucleotide design needed to be optimized.
First, it was necessary to generate mutations that avoid
the mismatch repair (MMR) system, which (in E. coli)
can be achieved by having three or more consecutive
base pairs altered or creating an oligonucleotide in which
a C·C mismatch is generated [8,9]. Such mutations are
poorly recognized by MMR and successfully avoiding
MMR can increase SSDR by approximately 100-fold [8].
Second, for optimal levels of SSDR, oligonucleotides
must be identical to the lagging strand of DNA synthesis,
which is replicated as short Okazaki fragments in a dis-
continuous manner [11,12]. This is likely due to the fact
that during synthesis of the lagging strand there is much
more template DNA available for binding than found on
the continuous leading strand synthesis template.
Although it is not entirely clear how oligonucleotides are
incorporated into the chromosome, it is possible that
they either serve as primers for Okazaki fragment synth-
esis or they are ligated into the DNA as if being recog-
nized as an Okazaki fragment. Third, modification of the
oligonucleotide to avoid degradation of host exonucleases
can improve SSDR efficiency. Placing phosphorothioate
linkages at the 5’ end of the oligonucleotide has been
shown to improve SSDR in several studies [13-17].
Although SSDR has been an extremely successful tool
for use in E. coli, there has been relatively little success
in establishing recombineering at the necessary efficien-
cies to generate unselected mutations in other bacteria.
However, the presence of recT homologs throughout
bacteria, and the ability of Gram-positive RecT proteins
to function as well as Beta in E. coli [18], suggested that
it should be possible to establish SSDR in a wide range
of organisms. Below, we describe the application of
SSDR in two different lactic acid bacterial species, Lac-
tobacillus reuteri and Lactococcus lactis. In both species,
subtle mutations, yielding an in-frame stop codon or a
single amino acid change, can be introduced into the
chromosome at efficiencies ranging from 0.3-20%,
depending on the chromosomal location. We will sum-
marize the salient features of SSDR in L. reuteri and
L. lactis and highlight key differences that need to be
considered when attempting to establish SSDR in other
LAB species. Several parameters needed to be optimized
to establish efficient SSDR in L. reuteri ATCC PTA
6475 and L. lactis NZ9000, which we expect will serve
as a blueprint for establishing this technology in other
Gram-positive bacteria. Topics discussed below will
include the minimal requirements to establish SSDR,
followed by a detailed description of the three key para-
meters that need to be taken into consideration when
designing oligonucleotides for SSDR in lactic acid bac-
teria in order to implement this technology in your
organism of choice at levels that do not require selec-
tion strategies to identify a mutant genotype.
SSDR in lactic acid bacteria
Choosing a suitable source of recombinase for SSDR
Phage-derived single-stranded DNA binding proteins are
highly divergent in both their amino acid composition
as well as their activity. Elegant work from Donald
Court’s group showed that recombinases from a phylo-
genetically diverse set of hosts displayed activity in
E. coli [18]. Remarkably, a RecT protein isolated from
the lactic acid bacterium Enterococcus faecalis yielded
similar level of recombinants compared to phage
Lambda-derived Beta protein in E. coli. This finding
suggested that recombinases in LAB are as active as
those previously characterized in E. coli and provided an
impetus for screening for active recombinases in lacto-
bacilli. L. reuteri 6475 encodes two RecT proteins, and
each has high-level activity in SSDR when produced in
trans from an expression vector [19]. However, it is not
necessarily best to use a native RecT when establishing
SSDR in your organism of choice. We found it is not an
absolute requirement to use the L. reuteri RecT proteins
for SSDR in L. reuteri as we have demonstrated that the
E. faecalis RecT protein has equal activity as the endo-
genous RecT proteins in L. reuteri 6475. In addition, in
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L. plantarum BAA-793 expression of the endogenous
L. plantarum RecT protein yielded many fewer recombi-
nants compared to when RecT derived from L. reuteri
6475 was expressed (unpublished data). Therefore, RecT
isolated from different sources may need to be tested to
identify the most active recombinase in a particular
strain background.
Transformation efficiency
To introduce single-stranded DNA (i.e. oligonucleotides)
into the cell, an efficient electroporation protocol must
be available for the bacterium of interest. Although the
efficiency at which ssDNA enters the cells may be differ-
ent compared to plasmid DNA, it is likely that when
plasmid DNA can cross the membrane, oligonucleotides
can likely do the same. Therefore, establishment of an
electroporation protocol may be done with plasmid
DNA but at a later stage electroporation settings may be
optimized with an oligonucleotide that, when incorpo-
rated in the chromosome, yields a selectable phenotype
such as rifampicin-resistance (see below for additional
details) to quantify the level of recombinants as a func-
tion of electroporation settings. Although we did not
assess the minimum transformation efficiency required,
in L. lactis a transformation efficiency of 105 colony
forming units per microgram (cfu/µg) of plasmid DNA
yielded sufficient levels of oligonucleotide in the cell to
isolate mutations without the need for antibiotic selec-
tion. Because the transformation efficiency of L. reuteri
6475 was poor when we started, we optimized the trans-
formation efficiency from 103 to 106 cfu/µg plasmid
DNA prior to attempting SSDR. Further improvement
of transformation efficiency to 107 cfu/µg plasmid DNA
did not result in a further increase in recombineering
efficiency, suggesting that either the SSDR efficiency or
the level of oligonucleotide that entered the cell had
saturated.
Inducible expression of the recombinase
Once oligonucleotides enter the cell, optimal levels of
the recombinase should be present to interact with the
oligonucleotide to promote annealing with the template
strand to form a complex for incorporation. We found
in L. reuteri 6475 that controlled expression of recT is
key for efficient oligonucleotide incorporation [19]. In
E. coli it was established that high levels of Beta expres-
sion for a prolonged period of time resulted in reduced
cell viability, which we also found to be true for pro-
longed RecT expression in L. reuteri 6475 [20]. A con-
stitutive, moderate level of expression of RecT in
L. reuteri 6475 was well tolerated but did not yield high
levels of recombinants. Only when RecT was induced
for a short period of time during growth levels of SSDR
were sufficient to isolate mutations without the need for
selection. Another reason to titrate the levels of RecT is
that in E. coli prolonged expression of Beta may increase
unwanted secondary mutations [21]. Thus, identifying a
system that allows controlled expression of RecT is
required for optimal SSDR.
A few inducible expression systems, both relying on
quorum sensing mechanisms to drive expression, have
been described for use in LAB, including the well-estab-
lished NICE (nisin controlled gene expression) system and
a sakacin-based system from Lactobacillus sakei [22-24].
Although both systems were extremely useful in a variety
of LAB strains to establish SSDR, not all strains are com-
patible with these expression systems. Therefore, the
development of a general expression platform based on
riboswitches, for example, may have merit for use in LAB
to extend SSDR to other LAB strains.
Oligonucleotide design considerations
Lagging strand Regardless of the target location in the
bacterial chromosome, an oligonucleotide for SSDR is
most efficiently incorporated when the oligonucleotide
sequence is identical to the lagging strand of replication
[11]. The lagging strand bias in E. coli, Mycobacterium,
L. reuteri, and L. lactis is approximately 30-fold, 10,000-
fold, 4,000-fold and 25-fold, respectively compared to
mutations generated with a leading strand oligonucleo-
tide [10,11,16,25]. Why L. reuteri and Mycobacterium
are more sensitive to lagging strand bias than the other
two strains is not clear. Thus it is important to be able
to identify which strand is the lagging strand of DNA
replication for optimal oligonucleotide design. Addi-
tional file 1 illustrates how one can identify the lagging
strand of replication, and provides detail on oligonucleo-
tide design to incorporate an in-frame stop codon in a
target sequence.
Evasion of the mismatch repair system Since a recom-
bineering oligonucleotide that anneals to the template of
the lagging strand at the replication fork would be consid-
ered part of the newly synthesized strand, the mismatch
repair (MMR) machinery will preferentially repair the
incoming oligonucleotide sequence back to wild-type.
This was confirmed in E. coli by showing the use of
mutants defective for MMR yielded large increases in
SSDR efficiency [8,9]. However, it is undesirable to per-
form recombineering in MMR mutants because many
unwanted mutations will occur at other sites in the gen-
ome. To circumvent this problem, oligonucleotides that
generate mismatches that are not well recognized by
MMR can be designed to mimic the increase in efficiency
observed in MMR mutants [8]. In E. coli, the hierarchy for
the efficiency of MMR to repair mismatches is reported
as G·T, A·C, A·A G·G > T·T, T·C, A·G > C·C [8]. We
observed that a similar hierarchy of MMR exists in L. reu-
teri 6475 (van Pijkeren et al. manuscript in preparation);
however, in L. reuteri 6475 the efficacy of repair seems to
be highly dependent on sequence context whereby the
sequence upstream and downstream of the mismatch(es)
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may impact the efficacy of MMR. Although a single C·C
mismatch may evade the MMR system in L. reuteri 6475
(van Pijkeren et al. manuscript in preparation) it becomes
problematic to identify a mutant when the mutation does
not allow for selection (see section Methods to screen for
mutations when no selection is performed). The most
straightforward approach to evade mismatch repair in
both L. reuteri and L. lactis is to design an oligonucleotide
that results in 4 or 5 adjacent mismatches when annealed
to the lagging strand template. We have shown in a
MMR-deficient derivative of L. reuteri 6475 that an oligo-
nucleotide containing 5 adjacent mismatches yields similar
levels of recombinants compared to the MMR deficient
strain, suggesting that MMR does not recognize multiple
consecutive mismatches in L. reuteri. Three adjacent mis-
matches can evade the MMR but only when cells are
transformed with high concentrations of oligonucleotide
(van Pijkeren et al. manuscript in preparation).
Oligonucleotide concentration In addition to having an
oligonucleotide that is identical to the lagging strand of
replication and can evade mismatch repair, a third
equally important parameter is the amount of oligonu-
cleotide that is transformed into the cell. In L. reuteri
6475 we found there is a strong linear and positive cor-
relation between the amount of oligonucleotide trans-
formed and the number of recombinants obtained when
transforming recombineering oligonucleotide within the
range of 1-100µg (37-3,780 pmol of oligonucleotide)
[16,19]. Similarly for L. lactis NZ9000, we found that
SSDR efficiency was linear, but this time up to 500µg of
oligonucleotide was required for optimal SSDR activity.
When optimizing the oligonucleotide concentration for
SSDR in L. reuteri 6475 and L. lactis NZ9000 we found
that 200µg and 1 mg oligonucleotide causes lysis in the
respective organisms, therefore we routinely use 100µg
and 500µg oligonucleotide for SSDR in L. reuteri 6475
and L. lactis NZ9000, respectively [16]. Importantly, the
use of such high levels of oligonucleotide does not lead
to increased mutation or insertion of the oligonucleotide
at other sites in the genome [19]. We did not investigate
the optimal oligonucleotide concentration in the other
LAB tested but we were able to obtain recombinants
when transforming 100µg oligonucleotide in L. plan-
tarum BAA-793 and L. gasseri ATCC 33323, therefore
this may be a good starting concentration when estab-
lishing SSDR in other LAB strains [19].
These oligonucleotide concentrations are in strong
contrast to the oligonucleotide concentration used in E.
coli, for example, in which recombination saturates with
5 pmol oligonucleotide [10], which represents approxi-
mately 10 oligonucleotide molecules per cell. Since
approximately comparable levels of L. reuteri and L. lac-
tis cells are transformed compared to E. coli (1010 cfu in
100µl) we can conclude that L. reuteri 6475 and L. lactis
NZ9000 require approximately 750-fold and 3,750-fold
more oligonucleotides per cell, respectively, to maximize
SSDR efficiencies. We have not investigated what the
rationale for this observation is but it is plausible that in
LAB less oligonucleotide enters the cell due to the cell
wall structure that is characteristic to Gram-positive
bacteria.
Guide to establish SSDR in other LAB
A graphical overview of SSDR is presented in Figure 1.
When establishing SSDR, the most convenient approach
is to modify the DNA of a gene that results in a select-
able phenotype to easily assess the level of recombi-
nants. We found that mutating the rpoB gene and
selecting for rifampicin resistance in various LAB strains
can efficiently determine the efficacy by which the
recombineering oligonucleotide is incorporated in the
chromosome. In order to identify mutations that yield a
rifampicin-resistant phenotype we analyzed the rpoB
sequences of several natural rifampicin-resistant colo-
nies, and confirmed that mutations in a codon coding
for a conserved histidine residue results in a rifampicin-
resistant phenotype (see Figure 1) in all four lactic acid
bacteria investigated [19]. Depending on the adjacent
codon it may be possible to make additional silent
mutations resulting in 4 adjacent mismatches which
evades MMR, yet the mutations will result in only a sin-
gle amino acid change (Figure 2). In L. reuteri 6475 that
was not possible, and we determined experimentally
whether additional amino acid changes yielded a viable
rifampicin resistant phenotype [19].
To establish SSDR in LAB, a good place to start would
be to transform 100µg of an 80mer oligonucleotide that is
identical to the lagging strand of replication, with the
exception of 4-5 adjacent, centrally located non-homolo-
gous bases which are needed to evade MMR and to incor-
porate the mutations to yield a rifampicin-resistant
phenotype. The number of rifampicin-resistant cells rela-
tive to the total number of viable cells indicates the per-
centage of recombinants. This approach allows further
optimization of a variety of parameters, including expres-
sion of different recombinases, duration of recombinase
expression, efforts to reduce degradation of oligonucleo-
tides by the host nucleases (eg. PT linkages), oligonucleo-
tide length and concentration. We direct the readers to
recent reports that describe a variety of parameters that
can be optimized for SSDR [10,14,16,19,26,27].
We do not recommend targeting a gene that allows
screening based on a color phenotype, such as ß-galactosi-
dase when plated with X-gal as a substrate. With SSDR the
oligonucleotide directed mutation(s) are incorporated in
only one of the strands during DNA replication. In both
L. reuteri 6475 and L. lactis NZ9000 we have noted that,
when targeting a gene for mutagenesis by SSDR that can-
not be selected, single colonies on an agar plate are almost
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Figure 1 Overview of recombineering in L. reuteri. (i) Electrocompetent cells in which RecT is expressed are transformed with a
recombineering oligonucleotide. Transformation efficiencies of >105cfu/mg DNA are required for high recombineering efficiencies. Wavy black
lines with a red dot represent recombineering oligonucleotides with multiple non-complementary bases; the green circle represents a bacterial
cell; pJP042 is the sakacin-based expression vector that contains recT; the black double helix represents chromosomal DNA; expressed RecT
proteins are denoted in the cell. (ii) An oligonucleotide identical to the lagging strand contains multiple non-complementary bases that avoid
the mismatch repair system resulting in increased recombineering efficiency. (iii) Viable cells are recovered on antibiotic-free plates and
recombinants are detected by a mismatch amplification mutation assay-PCR (MAMA-PCR). Two oligonucleotides (blue) will yield a 1-kb fragment,
whereas a third oligonucleotide (red) will only be extended by the polymerase when the mutations are incorporated in the chromosome
yielding a second amplicon of 500 bp. As the recombineering oligonucleotide only targets one strand during DNA replication the colonies will
be of mixed genotype. The red dot on the chromosome indicates that the mutations are incorporated. (iv) Single colony purification is
performed to separate the wild-type genotype from the mutant genotype. (v) MAMA-PCR is repeated as described in section iii to identify a
pure genotype mutant. A 1:1 ratio of wild-type and mutant genotypes is suggestive that during replication a single chromosome is being
replicated per cell. (vi) The recombineering plasmid pJP042 can now be cured from the mutant strain by passaging bacteria without antibiotic
selection to yield a plasmid-free derivative (vii). (Reprinted by permission from Oxford University Press, © 2012).
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always a mixed population of cells representing both wild
type and mutant genotypes. Either during the recovery
phase after electroporation the chromosomes have not seg-
regated, or the chromosomes have segregated but due to a
clumpy phenotype or chain formation, single colonies
represent a mixed cell population. Therefore, a blue-white
screen to identify cells in which the ß-galactosidase gene
has been inactivated is not a good choice since it will be
impossible to quantify the absolute level of SSDR.
Methods to screen for mutations when no selection is
performed
Once the SSDR efficiency is high enough to allow identi-
fication of mutations without the need for selection,
genes can be targeted to make multiple mutations to
incorporate a stop codon, for example. In both organ-
isms, identification of mutants can be established by
MAMA-PCR [28], or PCR followed by a restriction digest
if a restriction site is incorporated. For gene inactivation
by incorporation of an in-frame stop codon in both
L. lactis and L. reuteri, we design the recombineering oli-
gonucleotide such that in addition to a stop codon addi-
tional mutations yield a restriction endonuclease
recognition site that is unique compared to the 500 bp
flanking regions. To identify a mutant genotype we apply
MAMA-PCR that uses three oligonucleotides in a single
reaction (Figure 1). We design the flanking oligonucleo-
tides such that these are located 500 bp upstream and
downstream of the target site, thus yielding a 1,000 bp
amplicon. When the recombineering oligonucleotide is
incorporated, four or five bases on the 3’-end of the
MAMA oligonucleotide can anneal to the mutated
sequence and will form a 500 bp amplicon with one of
the flanking oligonucleotides. Once the mutation is gen-
erated we isolate a pure mutant genotype by streaking
positive colonies for single isolates. In rare cases the
MAMA oligonucleotide may not work, and we can repeat
Figure 2 Base changes in the rpoB gene leading to an amino change of a conserved histidine gives rise to rifampicin resistance. a.
Local alignment of RpoB from four LAB strains that highlights a conserved histidine (highlighted by a single black dot above the sequence)
which has been found to yield rifampicin resistance in these LAB strains as well as in Bacillus subtilis and E. coli when another amino acid is
substituted in its place. Asterisks (*) below the alignment indicate a single conserved residue, a colon (:) represents residues which share strongly
similar properties and a period (.) indicates residues that have weak similar properties. b. An example of how to design an oligonucleotide that
will incorporate four consecutive mismatches while only altering the histidine residue. The leading and lagging strands are indicated while the
oligonucleotide is shown below in bold. - indicates the nucleotide found in the lagging strand is identical to the nucleotide in the oligo and the
base mismatches are indicated in bold letters. The successful incorporation of the oligonucleotide into the chromosome will eventually lead to
the alteration of the serine codon from TCA to AGC, which still codes for serine while the histidine codon (CAC) is changed to AAC (asparagine).
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the screen with only the flanking oligonucleotides. The
1,000 bp amplicon can subsequently be subjected to
restriction digestion analysis to identify colonies that
contain the mutant genotype.
SSDR also allows construction of a single base change.
A single C·C mismatch may not be recognized by the
MMR but, unless a novel restriction site is generated,
genotypic detection of a single base change will be chal-
lenging. MAMA-PCR will be unreliable as we noted that
at least 3-4 non-homologous bases on the 3’-end of
the oligonucleotide need to be present in order to obtain
reliable and reproducible results. Even with three non-
homologous bases we often noted false-positive ampli-
cons, and although PCR settings may be optimized, this
is not a desirable approach for high-throughput screen-
ings. Instead, a single base change can be generated in a
2-step SSDR approach. In the first round 5 adjacent
bases are mutated, followed by identification of the
mutant, and purification of the pure genotype. This
mutant can subsequently be subjected to a second round
of SSDR in which 4 out of the 5 bases will be reverted to
the wild type sequence, and also this can be screened by
MAMA-PCR. The end product will be a single base
mutation in the chromosome. In both steps the MMR
will be evaded, and mutants can be screened in a high-
throughput manner by PCR screen.
Future developments in precision genome engineering in
LAB: improving SSDR using CRISPR-Cas
A major limitation in adapting SSDR to other bacterial
hosts is the ability to achieve efficiencies that would
allow the modification of any site in the genome and
easily recover the mutants without selection. Recently, a
novel method for eliminating cells that have not incor-
porated a mutation into the genome using the Cas9
endonuclease, which is associated with a type-II clus-
tered regularly interspaced short palindromic repeats
(CRISPR) locus from Streptococcus pyogenes, has been
described [29-33]. Although a thorough discussion of
the entire family of the CRISPR-Cas adaptive immune
system in bacteria is beyond the scope of this review, we
briefly describe the salient features of type-II CRISPR-
Cas systems and how it has been adapted for use in pre-
cision genome engineering.
CRISPR-Cas systems function to keep foreign DNA
from invading into the cell and they do so by incorpor-
ating segments of the foreign DNA (denoted as proto-
spacers) into the genome (eg. phage DNA), likely via the
activities of Cas1 and Cas 2 that are universally found
associated with CRISPR-Cas systems (for reviews see
[34-36]). These newly incorporated sequences, termed
spacers, are located between short palindromic repeat
sequences in an ordered array. In addition to the spacer
sequence, a short 2-5 bp protospacer associated motif
(PAM) located adjacent to the spacer is found and is
critical for recognition of incoming foreign DNA by the
CRISPR-Cas system. Once a CRISPR locus has acquired
a spacer sequence that targets a particular phage, type-II
CRISPR-Cas systems have a RNA-directed endonuclease
(Cas9) that will cleave any DNA within the cell that is
identical to the spacer. While all types of CRISPR-Cas
systems require the crRNA to direct target cleavage,
type II systems require a second RNA denoted trans-
activating crRNA (tracrRNA). Although one function of
the tracrRNA is to assist in the generation of fully
mature crRNA, both RNA molecules are required for
Cas9 cleavage of target DNA. The two RNAs interact
with Cas9 to direct the endonuclease to DNA sequences
with 100% identity to the crRNA and that also have the
correct PAM sequence that is recognized by Cas9.
Because CRISPR-Cas systems cannot discriminate
between foreign DNA and the host DNA like restriction
systems, they can create double strand breaks in the
chromosome of the host cell (often termed “autoimmu-
nity”) [37]. The ability to home the Cas9 endonuclease to
specific targets in the chromosome has been exploited to
generate loss of function mutations in eukaryotic sys-
tems. Once Cas9 introduces a double-stranded break in
the DNA, eukaryotic organisms do not always repair the
damage back to the wild-type sequence due to pathways
such as non-homologous end joining - NHEJ. NHEJ can
join non-homologous ends that can result in insertions
or deletions at the target site, which most often leads to
loss of function mutations.
More than 120 reports of targeting CRISPR to generate
loss-of-function mutations in eukaryotic systems were
published last year. However, bacteria faithfully repair
double strand breaks (or in some cases have poor NHEJ
activities) and thus simply targeting CRISPR-Cas9 to a
specific locus is not sufficient to generate mutations.
Marraffini and co-workers combined SSDR technology in
E. coli with CRISPR-Cas9 to generate mutations in the
chromosome that conferred streptomycin resistance
(rpsL). They found that ~65% of the cells that survived
dual SSDR/Cas9 modification incorporated the mutation
into the correct location of rpsL, a 1,000-fold improve-
ment of SSDR (the mutation they constructed was sub-
ject to MMR and thus had reduced SSDR efficiency). The
efficiency of CRISPR-Cas9 in this experiment is not high
enough to allow isolation of recombinants in which
SSDR is not efficient enough to generate mutations with-
out selection. However, it is likely only a technical hurdle
to improve CRISPR-Cas9 in bacteria such that >99.99%
of non-recombinants can be eliminated. Once this is
achieved, almost any organism that low SSDR activity
(either naturally or by inducing the expression of RecT)
will be able to be modified at nearly any site in the chro-
mosome. A schematic for how SSDR coupled with
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Figure 3 SSDR/Cas9 genome engineering. (i) A bacterial strain is transformed with a plasmid containing a Cas9 endonuclease along with a
tracrRNA. RecT activity can be provided either in trans on another plasmid or if the bacterium has a RecT protein in the native chromosome
endogenous recombinase activity may be sufficient if recombineering activity is high enough. The strain is made electrocompetent and an
oligonucleotide containing the desired mutation to be incorporated (denoted by red circle). (ii) Incorporation of the oligonucleotide (green)
ultimately results in the alteration of G-G for T-T, which will disrupt the PAM site (iii). Note that the PAM in this example (NGG) is variable
depending on the source of Cas9 utilized in the experiment. (iv) Electroporation of a plasmid containing a crRNA targeting the chromosome
into the population of recombineered cells. The crRNA will direct Cas9 to cleave the chromosome of the wild-type cells, while mutant
chromosomes will not be cut. By selecting for cells that contain the crRNA plasmid by antibiotic selection, only cells that have acquired the
mutation via recombineering and avoid Cas9 cleavage will survive.
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CRISPR-Cas9 would function in precision genome engi-
neering is shown in Figure 3.
Future prospects and directions
SSDR offers the ability for precision genome engineering
without the need for antibiotic selection. While several
challenges remain, the promise of using SSDR in combi-
nation with CRISPR-Cas9 to eliminate non-recombinants
means that genetic modification without the need for
antibiotic selection of many different bacterial strains and
species is likely to be available in the near future. The
identification of novel Cas9 proteins with different PAMs
will expand the number of sites available in a genome for
engineering [38,39]. Bacteria that harbor recT homologs
in their chromosome, like L. reuteri 6475, likely will not
require the introduction of RecT on a plasmid when
combined with Cas9 counter-selection due to the high
level of inherent SSDR activity in this strain. The devel-
opment of inducible expression systems will be required
for bacterial strains in which existing technology does
not work and have no endogenous SSDR activity.
Currently there are three bacterial species in which
SSDR can be performed to identify mutations without
the need for selection (Mycobacterial sp. are the fourth
but require co-selection of cells that have taken up
DNA to find recombinants). A major challenge moving
forward with SSDR in LAB will be the successful estab-
lishment of this technology in industrially and medically
important strains of LAB. Interestingly, E. coli and
L. lactis NZ9000 are lab-adapted strains that have been
passaged in the laboratory for decades and have similar
optimization strategies in SSDR. The lagging strand bias,
the ability of PT linkages to increase, and the overall
efficiency of SSDR similar between L. lactis and E. coli.
However, the incorporation of PT linkages does not
improve SSDR efficiency in L. reuteri and in fact may
inhibit SSDR, even though SSDR efficiency is quite a bit
lower than in the lab adapted strains [16]. L. reuteri
6475 is a human isolate and has had little exposure to
laboratory conditions. Working with other closely
related L. reuteri strains we find a wide range of recom-
bineering activity, indicating that other, yet unknown,
parameters for optimizing SSDR remain to be identified.
For example, the induction of temperate phages by the
introduction of large amounts of oligonucleotide may be
a major hurdle to overcome when working with strains
that have not been passaged in the laboratory.
SSDR now provides us with the ability to make gen-
ome changes, yielding an in-frame stop codon or a sin-
gle amino acid change, leaving no trace of foreign DNA
in the cell. In fact, using SSDR we can mutate a single
base whereas strains that have undergone a long selec-
tion procedure will most likely contain multiple base
changes. Taken this into consideration, a GMO strain
engineered by SSDR should be subjected to at least the
same risk assessment procedures as a non-GMO deriva-
tive which may contain multiple bases changes for
which we do not know how they change gene function
(s) and phenotypes.
Although GMO regulations differ in different regions
of the world, the ability to construct strains that are
genetically identical to strains that were “selected natu-
rally” or modified using non-GMO technologies demon-
strates that simply using a plasmid to construct a strain
does not yield a strain that is inherently any more dan-
gerous than non-GMO strains. Consider the following
hypothetical example: a researcher would like to generate
a probiotic bacterium that is resistant to high concentra-
tions of human bile. To isolate such a resistant mutant,
the cells are plated in the presence of bile, a bile resistant
mutant is isolated and its genome is sequenced. A single
base pair alteration in the hypothetical gene bilE is iden-
tified as the mutation yielding the bile resistant pheno-
type. Utilizing SSDR technology, this identical mutation
in bilE is constructed in the probiotic organism with the
subsequent plasmid containing recT removed. Deep
sequencing technology allows us to confirm that no for-
eign DNA remains in the cell, and no additional muta-
tions have occurred. Thus we have two strains that, by
any measure, are genetically 100% identical. If the reason
for designating a strain as GMO is for public safety, then
there were no reason to believe that in the above example
a strain mutated by SSDR would be less safe than a
genetic identical non-GMO derivative.
In summary, SSDR provides researchers with a valuable
tool with which to probe functions of industrially and
medically important strains of LAB. The revolutionary
aspect of SSDR is the fact that virtually any region of the
genome can be altered, which means that the rate-limit-
ing step in LAB genetics will soon be figuring out what
types of mutations you want to construct rather than the
genetic tools available for study. Combined with other
emerging technologies, such as CRISPR-Cas9, we envi-
sion a future in which strains can be engineered in ways
that are not only beneficial but also more safely con-
structed by avoiding unwanted mutations associated with
“non-GMO” approaches that allow the use of mutagens
in the selection of bacteria with desirable phenotypes.
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